Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for HROW.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 -0.466M
March 31, 2026 48.91M
December 31, 2025 -5.044M
September 30, 2025 4.964M
June 30, 2025 -12.67M
March 31, 2025 0.023M
December 31, 2024 29.98M
September 30, 2024 -0.721M
June 30, 2024 0.073M
March 31, 2024 -0.809M
December 31, 2023 -0.018M
September 30, 2023 64.20M
June 30, 2023 0.189M
March 31, 2023 62.16M
December 31, 2022 55.03M
September 30, 2022 0.00
June 30, 2022 -0.111M
March 31, 2022 -0.776M
December 31, 2021 -0.002M
September 30, 2021 0.015M
June 30, 2021 52.24M
March 31, 2021 -0.781M
December 31, 2020 -0.77M
September 30, 2020 -0.761M
June 30, 2020 2.966M
Date Value
March 31, 2020 -0.002M
December 31, 2019 0.635M
September 30, 2019 -0.413M
June 30, 2019 -0.455M
March 31, 2019 -0.773M
December 31, 2018 1.411M
September 30, 2018 2.469M
June 30, 2018 0.349M
March 31, 2018 -0.098M
December 31, 2017 0.695M
September 30, 2017 2.123M
June 30, 2017 -0.627M
March 31, 2017 2.739M
December 31, 2016 8.893M
September 30, 2016 1.975M
June 30, 2016 -0.056M
March 31, 2016 13.86M
December 31, 2015 0.301M
September 30, 2015 -0.054M
June 30, 2015 10.50M
March 31, 2015 -0.005M
December 31, 2014 -0.0186M
September 30, 2014 0.1342M
June 30, 2014 0.1329M
March 31, 2014 0.3496M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Viatris, Inc. -1.243B
Zevra Therapeutics, Inc. 1.585M
Indivior Pharmaceuticals, Inc. -172.64M
Liquidia Corp. -6.614M
60 Degrees Pharmaceuticals, Inc. 0.00